882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS.

@article{Kristeleit2014882PDPHASE1S,
  title={882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS.},
  author={Rebecca Sophie Kristeleit and Ronnie Shapira-Frommer and Ha. Burris and Miten Patel and Patricia M. LoRusso and Amit M Oza and Judith Balma{\~n}a and Susan M Domchek and Lingyun Chen and Ana Montes and Ruth Plummer and Hendrik-Tobias Arkenau and Lara Maloney and Erin Dominy and Geoffrey I Shapiro},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2014},
  volume={25 suppl_4},
  pages={iv307-iv308}
}
R. Kristeleit1, R. Shapira-Frommer2, H. Burris3, M.R. Patel4, P.M. Lorusso5, A. M. Oza6, J. Balmaña7, S.M. Domchek8, L. Chen9, A. Montes10, R. Plummer11, H. Arkenau12, L. Maloney13, E. Dominy14, G. Shapiro15 UCLH Dept. of Oncology, UCL University College London, London, UK Chaim Sheba Medical Center, Tel Hashomer, ISRAEL Dept. Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA Oncology, Florida Cancer Specialists, Sarasota, FL, USA Research Administration, Karmanos Cancer… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.

  • Therapeutic advances in medical oncology
  • 2017
VIEW 1 EXCERPT
CITES METHODS

Similar Papers